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Abstract: Background: Extra-intestinal manifestations of inflammatory bowel disease (IBD) are 
widely studied. Oral manifestations are manifold, miscellaneous, and hardly detected by general 
practitioners and gastroenterologists. Objectives: The main purpose of this systematic review is to 
find all the possible correlations between inflammatory bowel disease and the oral cavity in order 
to underline the importance of multidisciplinary cooperation with dental care providers, and to 
secure better treatments for patients. Materials and methods: Articles were searched up to June 2019 
through Ebsco’s, Google Scholar, and PubMed databases. The search terms included IBD, oral 
manifestations of inflammatory bowel disease, oral manifestations of Crohn’s disease or Ulcerative 
colitis, an extra-intestinal manifestation of IBD, oral Crohn’s disease, and paediatric inflammatory 
bowel disease. Discussion: The prevalence of the oral manifestation of IBD ranges from 0.7% to 37% 
in adults and from about 7% to 23% in children. They can be divided into specific manifestations 
(cobblestoning mucosa, mucosal tags, cheilitis granulomatosa, pyostomatitis vegetans) and 
nonspecific manifestations (halitosis, dysphagia, aphthous ulcerations, deep oral fissuring, cheilitis 
angularis, taste changes, lichen planus). Moreover, the link between IBD and the higher prevalence 
of dental caries and periodontitis have also been studied. Conclusions: The presence of oral 
manifestations that precede or follow intestinal symptoms of IBD, must be taken into serious 
consideration from both gastroenterologists and dentists in order to allow for early diagnosis and 
improve patients’ quality of life. 
Keywords: inflammatory bowel disease; Crohn’s disease; ulcerative colitis; oral manifestations 
 
1. Introduction 
Inflammatory bowel disease (IBD) is a group of nosological entities that comprises two major 
pathological conditions affecting the gastrointestinal tract (GI): Crohn’s disease (CD) and Ulcerative 
Colitis (UC). Its etiopathological mechanism is still unclear, but it is thought to be multifactorial, 
involving genetic, environmental, bacterial and immune response connections to the microbiota. 
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It can affect the entire GI tract, from mouth to anus, primarily involving the small intestine (CD) 
or the large intestine (UC). The age of onset of symptoms usually varies between 15 and 30 years [1], 
but the disease can occur at any age. 
The main symptoms are chronic diarrhoea (often bloody), abdominal pain, weight loss, fever, 
secondary anaemia, and fistulas. It can also have extra-intestinal manifestations (EIMs), with a 
prevalence rate varying widely from 16.7% to 40% [2,3], affecting the eyes, skin, joints, and the oral 
cavity and it appears to be more common at the onset in paediatric patients [2]. The different ages of 
study participants and the skills of the examiners performing the evaluation are the causes of that 
wide variability in assessing it’s prevalence. 
Oral manifestations of IBD can be specific or nonspecific, due to intestinal malabsorption or 
induced by pharmacological treatments. 
A few of these manifestations, such as aphthae, buccal mucosal swelling, mucosal tags, deep 
liner ulcerations, and cobblestoned oral mucosa are more indicative of CD, while pyostomatitis 
vegetans is correlated to UC. 
Especially, orofacial granulomatosis (OFG), a rare condition characterised by swelling of the lip 
and the oral cavity, must be investigated in young children, because it can conceal underlying 
Crohn’s disease or be a presenting feature of other systemic diseases [4]. 
Oral manifestations might precede IBD’s diagnosis (12.7–21%) [2,5], or coincide with it and 
interfere with therapy. 
A proper oral evaluation in paediatric patients must be conducted, particularly in children with 
OFG, in order to ensure early diagnosis and appropriate treatments. 
Moreover, several studies have also demonstrated a higher frequency of dental caries and 
periodontal disease [6–9]. 
Objective: The aim of this review is to highlight all the various aspects and possible links 
between IBD and oral manifestations, in order to evaluate the role of dentists and dental cares in 
improving patients’ oral health and consequently their quality of life. 
All the various aspects and possible links between IBD and oral manifestations were 
investigated in a number of case-control, cohort, and cross-sectional studies. 
2. Materials and Methods 
A systematic review was conducted up to June 2019, according to the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines [10], using the databases 
EBSCO-host, PubMed, and Google Scholar. The search terms included IBD, oral manifestations of 
inflammatory bowel disease, oral manifestations of Crohn’s disease or Ulcerative colitis, an extra-
intestinal manifestation of IBD, oral Crohn’s disease, and paediatric inflammatory bowel disease. 
Studies included in this review matched the predefined criteria according to the PICOS (patients, 
intervention, comparator, outcomes, study design) process as reported in Table 1. 
The exclusion criteria were review papers, case reports, papers published before 2000, papers 
not written in English, papers not mentioning oral manifestations, papers including other bowel 
diseases not universally recognised among IBD, such as Behçet syndrome. Papers linking the 
connections between disorders of the oral cavity and IBD in patients of all ages were included in this 
review. 
From each study, data about the demographics of participants (age and sex), oral sign and 
symptoms, caries and periodontal indices if detected, pharmacological treatments prior to the study, 
and that could have influenced the symptoms and smoke habits were collected. 
A study was found eligible when it fit all the inclusion, and none of the exclusion criteria. 
Duplicates were removed and they were screened by the title, abstract, and full text. Once a paper 
was found to fit the eligibility criteria, its references were, in turn, screened in order to find new 
papers previously missed. 
The risk of bias in each individual study was assessed using the Newcastle Ottawa scale (NOS) 
[11]. The quality score for every single study is reported in Tables 2, 3 and in a customized modified 
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version for cross sectional studies (Table 4) as explained in Figure 1. A low score does not necessarily 
denote an inappreciable study since it is the result of very strict and structured guidelines. 
Table 1. PICOS = patients, intervention, comparator, outcomes, study design. 
Parameter Inclusion Criteria Exclusion Criteria 
Patients 
Patients from 0 to 99 years with 
IBD 
Patients with another bowel disease not 
universally recognized as IBD 
Intervention Not applicable  
Comparator Not applicable  
Outcomes 
Diagnostic accuracy 
Connections between oral 
pathology and IBD 





Prospective, retrospective or 
concurrent cohort studies 
Cross sectional studies 
• Reviews, expert opinion, comments, letter 
to editor, case reports, conference report. 
• Studies not published in English 
• Studies published before 2000 
 
Figure 1. Newcastle Ottawa scale modified for cross sectional studies.
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Table 2. Assessment of the quality in cohort studies. Each item is given one star, except comparability which is given a maximum of 2 stars, up to nine total stars. 
In order to have an outcome all the patients must be exposed to inflammatory bowel disease (IBD), so the item regarding the selection of non exposed cohort is zero 
for all the studies taken into consideration. 













that outcome of 
interest was not 
present at start of 
study 
Comparability of 
cohort on the 

















et al. [2] 




* / * / ** (age, sex) * / / 5/9 
Jose et 
al. [5] 
* / * / 
** (age at 
diagnosis, type 
of EIM) 
* * / 6/9 
Khouri 
et al. [4] 
/ / * / / * * / 3/9 
Zippi et 
al. [3] * / * / 





* * * 7/9 
Legend: * = presence of the outcome / = absence of the outcome EIM= extra intestinal manifestation. 
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Table 3. Assessment of the quality in case-control studies. Each item is given one star up to a total of nine stars. 





























Brito et al. [6] * * / * *(age) (other 
factors) 
* * / 7/9  
Elahi et al. [13] * * / * *(age) *(sex) * * / 7/9  
Grössner-
Schreiber et al. 
[7] 
* * / * *(age) 
*(other 




* * / * *(age) 
*(other 
factors) 
* * / 7/9  
Katz et al. [14] * / / * *(age) *(sex) * * / 6/9  
Koutsochristou 
et al. [9] 
* / / * *(age) *(other 
factors) 
* * / 6/9  
Laranjeira et al. 
[15] 
* * / * *(age) 
*(other 
factors) 
* * / 7/9  
Mohan Kumar 
et al. [16] 
* / / * *(age) *(sex) * * / 6/9  
Rikardsson et 
al. [17] 
* * / * *(age) *(sex) / * * 7/9  
Szymanska et 
al. [8] * * / * *(age) 
*(other 
factors) * * * 8/9  
Zervou et al. 
[18] 
* / / * *(age) *(sex) * * / 6/9 
Legend: * = presence of the outcome / = absence of the outcome. 
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Table 4. Assessment of quality in cross sectional studies. Each item is given one star, except comparability which is given a maximum of two stars, up to a total of 
nine stars. 












Comparability of subjects 








* * * / ** (age, sex) * / 6/9 
Legend: * = presence of the outcome / = absence of the outcome. 
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3. Results 
In this review, seventeen papers following the search criteria were included, and data collected 
in 15 different countries, up to a total of 6692 study participants (2174 of which were under 18 years 
old). The database research identified 396 studies, but as depicted in the flow diagram (Figure 2), 
after removing the duplicates and screening the abstracts, only 109 were fully read and 92 excluded 
because they were irretrievable, irrelevant, or were not eligible after applying the exclusion criteria. 
Among the 17 papers, there were one cross-sectional study, one prospective study, four retrospective 
studies, eleven case-control studies with a total of 5369 (3558 with CD and 1811 with 
UC/indeterminate colitis) patients with IBD among all the different studies. 
In all the seventeen studies selected for the review, the main purpose was to identify oral signs 
and symptoms related to IBD (whether they were early manifestations of a systemic disease or they 
coexist with the main medical condition) and the secondary purpose was to relate IBD to two main 
oral conditions, caries, and periodontitis. 
As the study design, participants, primary, and secondary outcome varied markedly and the 
results were poorly distributed, we preferred not to perform a meta-analysis of the studies and rather 
focused on a description of their results, their limitations, and the possible developments. 
Each outcome for every single parameter considered in the systematic analysis, as already 
described, is observed in Table 5. 
 
Figure 2. PRISMA flow diagram. 
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IBD Patients n 
(M/F); Mean 
Age 
Oral Sign and 







Treatments Smoke Habits 
1 Brito et 
al. [6] 
CC; Brazil 253 (88/165);  
40.8 ± 22.5 yr  
Cr = 74 
(24/50); 40.3 
± 12.9 yr 
CD=99 (31/68); 
39 ± 12.9 yr  
UC = 80 (33/47); 
43.3 ± 13.2 yr 
Candidiasis = 20 (8 
CD, 8 UC, 4 Cr) NS 
ulcerous aphtous = 3 
(2 CD, 1 UC) NS 
lichen planus = 5 (1 
CD, 3 UC, 1 Cr) NS 
CD = 15.1 ± 7.2  
(p = 0.018)  
UC = 16.4 ± 6.6  
(p < 0.0001)  
Cr = 12.5 ± 6.8 
CD :PPD = 2.3 ± 1.3 
mm (p < 0.0001)  
CAL = 0.9 ± 0.9 mm 
NS 
% of sites with BOP = 
19.6 ± 20.5 (p = 0.038) 
Periodontitis = 81 
(81.8%)  
Cr: PPD = 1.6 ± 0.4 
CAL = 1.2 ± 1.0; % of 
sites with BOP = 24.4 ± 
29.7     Cr 
periodontitis = 50 
(67.6%). 
UC :PPD = 2.3 ± 0.4 (p 
< 0.0001) CAL = 1.3 ± 
1.4 (p = 0.004) 
% of sites with BOP = 
21.5 ± 21.9 NS 







CD: smokers = 12 (12.1%) 
non-smokers = 63 (63.3%) 
former smokers = 24 (24.3%). 
UC: smokers = 7 (8.7%) 
non-smokers = 38  (47.5%) 
former smokers = 35 (43.8%) 
Cr: smokers = 9 (12.2%) 
non-smokers=57 (77%)  
former smokers = 8 (10.8%) 
2 Elahi et 
al. [13] 
CC; Iran 100 (54/46); 
39 ± 25,6 yr.   
Cr = 50 
(26/24); 40 ± 
20 yr 
UC = 50 (28/22); 
38 ± 16 yr 
Oral ullerations = 20 
(p = 0.028);  
tongue coating = 14 
(p = 0.012);  
dry mouth = 30 (p = 
0.023);  
halitosis = 34 (p = 
0.001);  
acidic taste = 20 (p = 
0.008),  
taste changes = 20 (p 
0.001) 
NN NN NO NN 
Diagnostics 2019, 9, 77 9 of 19 
 
3 Greuter 






55 had at 
least 1 EIMs 
(39 CD, 12 
UC, 4 NS) 
CD = 173 
(104/69); 12 yr. 
UC/ND = 156 
(77/79); 11 yr 
 
aphtous stomatitis = 
24 (5 CD, 18 UC,1 
NS) (7.3% of the 
entire study 
population but 
43.6% of 55 patients 
with EIMs 












38.3 ± 14.3 
yr.  
Cr = 59 
(24/35); 38,2 
± 10 yr 
CD = 46 
UC = 16 
Mucobuccal 
hyperplasia or 
oedema = 15, 
swelling of the 
gingiva = 17, 
ulcera = 5,  
Aphthae = 6,  
Candidiasis = 5,  
lichen planus = 3, 
leucoplachia=2, 
labial rhagades = 3 
DMF-S (p 0.212 
NS 
IBD = 54.1 ± 31.6.  
Cr = 46.5 ± 26.5 
Dentine caries: 
(p = 0.033) 
IBD = 25 (40%);  
Cr = 13 (22%) 
BOP (p = 0.958) NS 
IBD = 23.4 ± 20.1; Cr = 
20.8 ± 13.5.  
PPD (p = 0.014) 
IBD = 2.22 ± 0.57; Cr = 
2.29 ± 0.33. (p = 0.014)  
CAL>4 mm: (p = 0.07) 
IBD = 50 (81%). Cr= 38. 
(64%)  
CAL>5mm: (p = 0.07) 









IBD nonsmokers = 34 (55%) 
IBD smokers = 25 
IBD former smokers 
= 3 (5%); 
Cr nonsmokers = 29 (49%)  
Cr smokers = 24.  
Cr former smokers = 6 (10%) 
5 Habashn
eh et al. 
[1] 
CC; Jordania 260 
(156/104); 
39.4 ± 0.7 yr 
Cr = 100 
(62/38) 
CD = 59 (33/26) 
UC = 101 (61/40) 
NN NN CD: PPD = 1.29 ± 0.47; 
CAL = 1.95 ± 0.98. 
% of sites with BOP = 
10.84 ± 16.20 
gingival recession = 
0.53 ± 0.55 
UC: PPD = 1.51 ± 0.47; 
CAL = 2.36 ± 1.13 
% of sites with BOP = 
10.20 ± 14.25 
gingival recession = 
0.86 ± 0.72 
Cr; PPD = 1.25 ± 0.37, 
CAL = 1.70 ± 0.89 
% of sites with BOP = 
4.70 ± 8.30 
gingival recession = 
0.44 ± 0.60 
NN CD 
Nonsmoker = 23; Smoker = 
31; ex-smoker = 5 
UC 
nonsmoker = 55; smoker = 
17; ex-smoker = 29 
Cr 
nonsmoker = 44; smoker = 
49; ex-smoker = 7 
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6 Harty et 
al. [12] 
P; Ireland 80 CD = 49 (25/24); 
11,95 yr  UC = 
22   ND = 9 
oral CD = 20 
(12/8) 11.4 yr 
non oral CD = 28 
patients with oral 
CD compared to 
nonoral CD: 
oral symptoms = 14 
(70%) (p = 0.01) 
mouth ulcers = 11 
(55%) NS 
angular stomatitis = 





NN nonspecific gingivitis 
= 8 (16.7%) 
NN NN 
7 Jose et al. 
[5] 
R/P; USA 1649 
(893/756); 
11.1 ± 4.15 
CD = 1007.  UC 
= 471.   ND = 
171 
53 patients with 
aphthous stomatitis 
(13.7% of all EIM) 
before diagnoses 
NN NN NN NN 
8 Katz et 
al. [14] 
CC; Israel 96 (49/47); 
38.5 ± 26.9    
Cr:42 
(22/20); 40 ± 
20 yr 
CD = 34 (20/14); 
33 ± 16 yr  
UC = 20 (7/13); 
44 ± 18 yr 
Halitosis = 50% UC 
(p = 0.0008); 29% CD, 
(p = 0.026) 
dry mouth = 30% 
UC, (p = 0.04); 29% 
CD (p = 0.026) 
geographic tongue = 
15% CD (p = 0.01), 
dysphagia = 15% 
UC, (p = 0.05); 9% 
CD NS 
nausea = 30% UC (p 
= 0.017), 50% CD (p = 
0.001) 
vomiting = 15% UC, 
NS; 41% CD(p = 
0.01) 
regurgitation = 45% 
UC,(p = 0.017); 21% 
CD, NS 
NN NN NN NN 
9 Khouri et 
al. [4] 
R; Australia 6 (5/1); 6.33 
yr 
 
CD = 4 M; 6.25 
yr 
Lip swelling = 6, 
granulomatous 
cheilitis = 6, 
cobblestoning 
mucosa = 2 
NN NN NN NN 





CC; Greece 110 (50/60); 
12.26 ± 5.22 
yr    Cr = 
55 (25/30); 
12.21 ± 3,96 
yr 
CD = 36 (18/18); 
UC = 19 (7/12); 
13 of 55 patients 
had oral lesions 
(23%) 
Aphthae = 8, 
aphthae with 
swelling of gums or 
ulcers or candidiasis 
= 5 
DMFT        
IBD = 5.81 (p < 
0.001)      
Cr = 2.04        
dmft         
IBD = 2.95 (p < 
0.001)     
Cr = 0.91    
CPITN index: 
IBD: score 0 = 0 (0%)  
score 1 = 20 (36%) 
score 2 = 30 (54%)  
score 3 = 5 (9%)  
Cr: score 0 = 22 (40%)  
 score 1 = 25 (45%) 
score 2 = 8 (14%)  













45.5 ± 16.9 
yr.         
Cr = 58 
(28/30); 47.4 
± 16.3 yr 
CD = 65 (32/33); 
41.1 ± 15.2 yr.   
UC = 48 (25/23); 
49.2 ± 18.4 yr 
Aphtous ulcers = 1 0 
(8.80%), (p = 0.159 so 
NS);  
gingival swelling = 1 
(0.90%),     angular 
cheilitis = 1 (0.90%),  





Non smokers  
Cr = 52 CD =52; UC = 42 
Smokers  




CC; India 30 (16/14) UC = 15 (8/7) Aphtous ulcerations 
= 10 
lichen planus = 3 dry 
mouth = 11  
PSV = 1, coated 
tongue = 4 NS 
dysgeusia = 5, 
halitosis = 12 
NN Periodontal status NS: 
Periodontal index UC 
= 1. Cr = 1.4  
gingival index UC = 
1.2 Cr = 1.3  
loss of attachment 
(mm) =  





et al. [19] 
T; Chile 30 (9/21); 40 
yr 
CD = 7 (2/5) UC 
= 23 (7/16) 
11 patients (37%):    
Oral ulcerations = 1 
Apthae = 4, angular 
ulcer = 1, 
macrocheilia of the 
lip, corrugated 
mucosa 
NN NN NN NN 
14 Rikardss
on et al. 
[17] 
CC; Sweden 2346 
(32.5%/67.5
%); 49.6 ± 
20,60  Cr = 
748 
(33%/67%); 
49.5 yr ± 13.8 
yr 
CD = 1598 
(32%/68%); 49.7 
± 15.3 yr 
Oral ulcers = 32% (p 
< 0.001), 
halitosis = 23% (p < 
0-001) 
mouth dryness = 
38% (p < 0.001) 
toothaches = 21% (p 
< 0.001) 
mucosal lesions = 
31% (p < 0.001) 
Carious lesions = 
41% (p < 0.001) 
bleeding from gingiva 
= 41% (p < 0.001) 
periodontitis = 7% (p < 
0.028) 
NN Current smokers 
CD = 23% Cr = 19% (p < 
0.018) 
former smokers 
CD = 19% Cr = 15% (p < 
0.070) 
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15 Szymans






47.1 ± 24.08 
yr  Cr = 75 
(29/46); 48.6 
± 13.4 yr  
CD with RS = 71 
(33/38); 50.7 ± 
13.9 yr  CD 
without RS = 79 
(40/39); 42 ± 14.4 
yr 
Dry mouth (p = 
0.001): 11% in 
Cr,29% in CD with 
RS and 38% in CD 
with NRS 
 Bad breath (p = 
0.008):12% in Cr, 
21% in CD with RS 
and 33% in CD with 
NRS  
Ulcers (NS) :23% in 
Cr, 23% in RS and 
27% in CD with NRS 
Cr = 13.1    
CD with RS = 
15,5. CD with 
NRS = 11.2 
NN NN Cr = 5  
CD with RS = 17 
CD with NRS = 15  
Former smokers  
Cr = 33  
CD with RS = 25  
CD with NRS = 30 
16 Zervou 
et al. [18] 
CC; Greece 74; 41,5 ± 20 
yr.  
Cr = 47;43 ± 
12 yr 
CD = 15 
UC = 15 
Ulcers = 3 (2 CD,13% 
(p = 0.011); 1 UC,7%, 
(p = 0.07)) 
cobblestoning = 3 
CD,20%, (p = 0.002) 
polypoids tags = 3 
CD,20%, (p = 0.002) 
lip swelling = 4 (3 
CD,20%, (p = 0.002); 
1 UC, 7%, (p = 0.07)) 
buccal swelling = 1 
CD,7%, (p = 0.07) 
aphthous ulcers = 1 
UC,7%, (p = 0.07) 
angular cheilitis = 9 
(5 CD, 33% (p = 
0.000); 4 UC,27%, (p 
< 0.0001)) 
Hairy tongue = 3 (2 
CD, 13%, (p = 0.011); 
1 UC (p = 0.07)) 
buccal trauma = 9 (6 
CD, 40%, (p = 0.000); 
3 UC, 20% (p < 
0.00019)) 
NN Periodontitis=2 CD 
13%, (p = 0.011) 
Gingivitis = 4 (3 CD, 
20%, (p = 0.002); 1 UC, 
7%, (p = 0.07))   
Gingival bleeding = 4 
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17 Zippi et 
al. [3] 
R; Italy 811 
(437/374); 
32.5 ± 18,9 




CD = 216 
(131/85); 31,9 ± 
13,1 yr.  UC = 
595 (306/289); 
33,1 ± 13,7 yr 
6 cases of aphtous 
stomatitis, 3 CD e 3 
UC (1.4% CD e 0.5% 
UC) 
NN NN NN CD         
Smoker = 98.     
Non-smoker = 101  
Ex smokers = 17.  
UC        
Smokers = 140.     
Ex smokers = 131.     
Non smokers = 324 
Legend: DMFT = decayed, missing, filled teeth index in the permanent dentition; dmft = decayed, missing, filled teeth index in the primary dentition; EIMs = extra 
intestinal manifestations; NN = unknown; NS = not statistical; p = p value; P = prospective study; CC = case control; T = cross sectional study; NRS = non resective 
surgery ; R = retrospective study; RS = resective surgery; ND = indeterminate colitis. 
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4. Discussion 
The prevalence of oral manifestations in IBD has been reported to range widely from 0.7% to 
37% [3,19] in adults and from 7.3% to 23% in children [2,9], data increasing up to 41% when 
considering only CD children [12]. 
The remarkable variability in the prevalence reported among the various studies may be due to 
the different design of the studies, the number and type of population, and in particular, the lack of 
experience of certain physicians (often gastroenterologists and not dentists) in finding and accurately 
classifying oral manifestations [12], and in the lack of uniqueness in classifying IBD oral changes, 
using different parameters, and therefore, making it difficult to compare the different results. 
Oral manifestation of IBD can be specific or nonspecific (Table 6) and can precede (12.7–21%) 
[2,5], or be the presenting sign of gut involvement. Mucocutaneous findings, mostly oral 
manifestations, can be asymptomatic presenting signs of IBD. 
Table 6. Specific and nonspecific manifestations of IBD. 
Specific manifestations 
Oral manifestations Crohn's disease Ulcerative colitis 
Cobblestoning the mucosa X  
Granulomatous cheilitis X  
Mucosal tags X  
Pyostomatitis vegetans  X 
Unspecific manifestations 
Deep oral fissuring  X  
Cheilitis angularis  X X 
Dental caries  X X 
Mucogingivitis  X X 
Periodontitis  X X 
Lichen planus  X X 
Dysphagia  X X 
Dry mouth  X X 
Halitosis  X X 
Taste changes  X X 
Aphthous ulcerations X X 
Legend: X = presence of the manifestation. 
The most common oral manifestation of IBD is aphthous stomatitis (aphthae with an atypical 
presentation or clinical course) [20] which occurs from about 0.7% to 20% [2,13] (this last one 
regarding only UC) in adults and from 3.2% to 41.7% in children [5,12]. They cannot be differentiated 
from regular aphthae unless a biopsy is performed, which must be based on clinical grounds, and 
thereby, is not always conducted if a histological IBD diagnosis is already available; they are as 
frequent as in the healthy population, but they have a tendency of recurring in time [19] and resemble 
the ulcers present in the gastrointestinal tract. They are described as the presence of small, painful 
but benign oral ulcers, circumscribed by an erythematous halo, and they can be isolated or part of 
recurrent aphthous stomatitis [20]; they usually occur on the buccal and labial mucosa or the 
vestibular sulci (Figure 3). In IBD patients, aphthous ulcerations may be caused by a deficit of iron, 
zinc, or vitamin B12 due to intestinal malabsorption and rectal bleeding linked to the main disease, 
or a side-effect of their pharmacological treatment. In children, the presence of oral ulcerations is not 
only painful, but has a significant impact on nutrition and can result in growth failure, development 
problems, and psychological adjustment. 
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Figure 3. Oral manifestations of IBD: apthous stomatis in the vestibular sulci. 
Furthermore, in children, aphthous stomatitis has proven to be the second most common EIM's 
[2,5] with a range from 3.2% to 7.3% of all patients with IBD, and the second most common EIM's to 
appear before diagnosis (21% according to Jose et al. [5] and 29% of cases for Greuter et al., [2] after 
peripheral arthritis. 
The debate is still open as to whether there is a link between the presence of aphthous ulcers and 
the activity phase of diseases (measured using the Harvey Bradshaw index, the Crohn's disease 
activity index for CD, the Montreal index of activity, or the Truelove and Witts criteria for UC). 
According to Laranjera et al. [15], aphthous ulcerations are the most common oral lesions in the active 
phase of the disease (p = 0.001) and oral symptoms were reported in 70.6% of patients in the active 
phase also, compared to 52.1% in remission with a particular association with dysphagia, 
regurgitation, and acidic taste. Elahi et al. [13] reported a higher statistical significance (p = 0.001) with 
oral ulceration in patients with severe UC compared to the controls. These data don't find validation 
in studies by Zervou et al. [18] in which, although a correlation between IBD and oral manifestations 
was found, it wasn't related to the active or inactive disease. Similarly, Grössner-Schreiber et al. [7] 
reported that only 38% of their study population showed a link between any oral lesion and IBD 
activity disease. Brito et al. [6] didn't observe any difference in oral lesions between IBD's and control 
groups and no correlations with disease activity. 
Therefore, any patient presenting a history of recurrent oral ulceration or referring any other GI 
symptomatology should be sent to a specialist evaluation. Topical applications of corticosteroids 
seem to give benefits along with systemic treatment of main bowel disease. 
Among the specific lesions correlated to CD, there are mucosal tags, cobblestoning of the 
mucosa, and buccal swelling linked to granulomatous cheilitis. Pyostomatitis vegetans is, on the 
contrary, mostly noted in UC patients. 
Cobblestoning of the mucosa is defined by a combination of deep, transversely, and 
longitudinally oriented ulcerations separating intact portions of mucosa giving the resemblance of 
cobblestones [21], and it can be seen in a range from 6% to 20%, respectively in children and adults 
[12,18]. 
Pyostomatitis vegetans is a rare oral disorder firstly observed by Hallopeau in 1898 and 
characterised by the presence of multiple white or yellow pustules on erythematous mucosa that 
undergo necrosis, rupture, and thus, result in a snail-track appearance [16]. 
It affects mostly UC patients and it appears on the labial and buccal mucosa, soft and hard palate, 
gums and rarely on the floor of the mouth. Histologically, it shows acanthosis, intraepithelial, and 
subepithelial abscesses with neutrophils and eosinophilic infiltrate [16]. As many of the oral 
manifestations of IBD, it resolves itself with adequate control of the underlying bowel disease. 
Another distinctive feature that can appear years before a proper diagnose of CD is cheilitis 
granulomatosa present in orofacial granulomatosis (OFG). Firstly identified by Wisenfeld et al. in 
1985 [22], OFG is a complex condition characterised by a non-caseating granulomatous inflammation, 
detected by a biopsy and affecting the oral cavity, particularly the lips, with no evidence of systemic 
involvement. It encompasses other diseases such as granulomatous cheilitis (GC) of Meischer, 
Melkersson-Rosenthal syndrome (MRS), oral Crohn’s disease, sarcoidosis, tuberculosis, and other 
infections and allergic conditions. 
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The main symptoms are recurrent and persistent buccal swelling (mainly lip swelling with 
angular cheilitis), gingival enlargements, oral ulcers, and sometimes facial palsy and cervical 
lymphadenopathy. Notably in young children, the occurrence of OFG, after having dismissed other 
possible infectious or allergic aetiology, is likely linked to Crohn's disease—in a report of six patients 
diagnosed with OFG, four developed CD within a few months [4]. In view of this, some authors 
suggest that all patients with OFG undergo a biochemical test (in particular faecal calprotectin test) 
and eventually a gastrointestinal endoscopy if symptoms are equivocal for a differential diagnosis 
between an early oral presentation of Crohn and OFG [4]. The treatments are not specific and include 
corticosteroids, topical with intralesional injections or systemic, thiopurines, and anti-Tumor necrosis 
factor-α (TNF-α) therapies. Sometimes, in the severe case of OFG, cheiloplasty may be taken into 
account. 
Oral lichen planus is a chronic inflammatory dermatosis that affects the oral mucosa and has six 
different clinical presentations, it can be reticular, erosive/ulcerative, bullous, plaque-like, papular, 
or atrophic (Figure 4). The aetiology is still unknown, but it is thought to being related to an immune-
mediated mechanism that involves dendritic cells and T cells. Oral lichenoid drug reactions have 
proven to be related to mesalazine and sulfasalazine [16] used in the therapy of IBD patients. 
  
Figure 4. Oral manifestation of IBD: lichen planus in the left buccal mucosa. 
In addition to oral lesions, there is a large group of oral symptoms, such as acidic taste, taste 
changes, halitosis, dry mouth, and xerostomia. An Iranian study from Elahi et al. [13] showed a 
significant statistical relationship particularly among halitosis (p = 0.001) and taste changes (p = 0.001) 
in UC adult patients with a statistical trend regarding the other parameters. Data were confirmed by 
Laranjera et al. (16) in an IBD sample with a prevalence of 54.9% in IBD patients and 29.3% in the 
control group (p = 0.011) and Katz et al. [14]. In this last study, beyond the statistical significance of 
halitosis in UC patients, nausea was identified in CD and vomiting, regurgitation, dry mouth, 
dysphagia, and geographic tongue were reported to have a statistical trend. Changes in the tongue 
(a hypotrophic or coated tongue, angiomas, fissures) have also been observed and are considered 
side effects of the iron and vitamin deficiency caused by rectal bleeding. Taste changes may be 
sometimes attributed to Metronidazole, an antibiotic used in the therapy of Crohn’s disease. These 
data must be taken cautiously because they are all based on questionnaires filled out by the patients, 
and consequently, there might be a bias in their ability to distinguish and report oral symptoms 
carefully. 
In regard to dental caries, a large, prospective Greek study from Koutsochristou et al. [9] 
analysed decayed, missing, filled teeth indexes for the permanent dentition (DMF-T) and decayed, 
missing, filled teeth indexes for the the primary dentition, (dmf-t) and found higher values of DMF-
T and dmf-t in children and adolescents with IBD (p < 0.001); nevertheless, the PCR index researching 
the presence of plaque was not statistically different from controls. These data find validation in 
another report from Brito et al. [6] on adult patients (p < 0.0001 for CD patients and p = 0.003 for UC 
patients). Grössner-Schreiber et al. [7]; however, using the (decayed, missing, filled surface (DMF-S) 
a modified version of the DMF-T index which is calculated per tooth surface) showed no difference 
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in DMF-S index between IBD’s and controls even though the first ones had higher plaque index and 
higher prevalence of dentine caries (46% in IBD vs. 22% in controls). 
Furthermore, Szymanska et al. [8] studied two groups of CD patients who either had or had not 
undergone resective surgery and compared them to healthy controls. CD patients who had 
undergone resective surgery had higher levels of DMF-S compared to controls and higher levels of 
plaque (reported using the visible plaque index), but in patients who had not undergone resective 
surgery, that was not true. The author correlated that outcome to the severity of the disease (in fact, 
there was a significant, although the weak correlation between the disease duration and the DMF-S 
index) and the presence of old restorations, a risk factor for new caries. 
The increase in dental caries risk is thought to be associated to dietary habits, changes in salivary 
and microbiological conditions of the oral cavity and malabsorption. Malabsorption of vitamin D, 
which has been proved to play a significant role in IBD patients [23], may possibly be related to the 
complex multifactorial etiopathology of dental caries [24], but more studies are required to assess the 
causative relationship between them. Furthermore, in order to mitigate the intestinal symptoms, 
patients usually switched to a fat-reduced and richer, refined carbohydrate diet, thus, increasing the 
risk of caries [17]. 
Mucogingivitis, an inflammation of the gingival tissues with an oedematous, erythematous, 
granular, and hyperplastic gingiva was observed by Harty et al. [12] in 12 of 48 children with CD and 
it’s one of the most common features of oral IBD. Zervou et al. [18] found a higher incidence of 
gingivitis and gingival bleeding in CD, but not in UC. 
A positive association between periodontitis and IBD has also been investigated. Habashneh et 
al. [1], in their sample population of Jordanian adults, observed that periodontitis was more severe 
and generalised, especially in UC patients. In particular, the average gingival recession was the most 
significant data and was higher in UC patients compared to those with CD (p = 0.007) and to controls 
(p < 0.005), the average gingival index and plaque index were also higher than the control population. 
These results have been mirrored by another study from Brito et al. [6] who focused on the effect of 
smoking as a modifier. Overall periodontitis was more common in IBD patients than controls, but it 
reached significance among smoking patients with UC versus smoking controls (95.2% versus 70.6%, 
p = 0.008), whilst this difference was not statistical in non-smoking UC and CD patients and controls 
(p = 0.057). Probing pocket depth (PPD), even after being adjusted for race, smoke, gender, age, and 
plaque, was still higher in CD and UC patients (p < 0.0001). These results; however, collided with a 
previous study from Grössner-Schreiber et al. [7] which revealed similar PPD in IBD patients and a 
control population that reached no significance and similarly other parameters, such as sites with 
CAL (clinical attachment loss) > 4, were higher in IBD but did not reach significance. 
Koutsochristou et al. [9] by contrast detected periodontitis in a population of children and 
adolescents in remission with the CPITN index (community periodontal index of treatment needs, 
an epidemiological index) in a population of children and adolescents, and found that none of them 
had a healthy periodontium (CPITN score 0), 36% had a CPITN score 1 (meaning only gingival 
bleeding), 54% had CPITN score 2 (gingivitis with gingival bleeding, calculus, and overhanging 
restorations), and 9% had CPITN score 3 (at least 1 site with PPD values between 4 and 5 mm). 
Whereas 40% of the control population had a healthy periodontium, 14% had gingivitis, and none of 
the subjects had 1 site with pocket. These data showed high statistical significance in patients 
compared to controls (p < 0.001). 
A correlation between IBD and periodontitis has, therefore, been determined, even though 
findings are not uniform, but in order to realise whether there are clinical implications for the 
management of periodontitis in patients with IBD further studies, on a larger scale, are necessary. 
Moreover, there are a few case reports indicating a correlation between TNF-α inhibitors and 
oral lichen planus [25] and between Infliximab (another TNF-α inhibitor) and oral ulcerations since 
it has been demonstrated to be immunogenic and leads to antibodies to infliximab related to painful 
oral ulcerations [26]. Although case reports have been excluded in this review, we think that these 
two studies may be worthy for further consideration, since no observational studies have been 
published. 
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Furthermore, links between the oral cavity and IBD aren’t restricted to mucosal involvements 
but affect the composition of the oral microbiome. A study from Docktor et al. [27] in a cohort of 114 
children demonstrated that CD patients, as opposed to UC and healthy patients, experiment a 
reduction of the biodiversity of the oral microbiome and particularly some phyla (Fusobacteria and 
Firmicutes) as happens in the intestinal microbiome. In regard to the oral manifestation, CD patients 
also have higher levels of anti-Saccharomyces cerevisiae antibody (ASCA), and this is also associated 
with an increase in disease activity. Russel et al. [28] examined 301 Scottish children and detected a 
correlation between a positive ASCA status and a severe grade of the disease. ASCA status may then 
be considered a useful marker for stratifying disease and potential treatments. 
5. Conclusions 
The presence of oral manifestations and symptoms in IBD, along with the higher risk of caries 
and periodontitis, must be taken into serious consideration. The cooperation of both 
gastroenterologists and dentists is crucial in order to achieve early diagnosis, better management of 
therapies, and improve patients’ quality of life. Further developments in research may also involve 
the search for new therapies and their possible impact on oral health. 
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